以肝星状细胞为靶标的抗肝纤维化治疗进展

The progression for the therapy of liver fibrosis targeting to hepatic stellate cells

任何病因导致的慢性肝损伤,均可发展为肝纤维化。损伤肝脏的纤维化形成过程中,活化肝星状细胞(HSC)是主要细胞类型,并有重要细胞因子参与。目前治疗都以阻止活化HSC在损伤部位聚集和细胞外基质沉积为目标。该文就以HSC为靶标的抗肝纤维化最新治疗方案作一综述。

Following chronic liver injury of any etiology, there is progressive fibrosis. The identification of activated hepatic stellate cells(HSCs) as the major fibrogenic cell type in the injury liver, as well as the recognition of key cytokines involved in this process, has facilitated the design of promising new antifibrotic therapies. These therapies aimed at inhibiting the accumulation of activated HSCs at the cites of liver injury and preventing the deposition of extracellular matrix. This review describes the current therapeutic approaches for liver fibro-sis, with hepatic stellate cells as a target.